Deck Bio

Deck Bio is an emerging biotechnology company focused on expanding the number of patients who can benefit from T cell engagers by overcoming fundamental market access barriers that limit this modality today. The company is expanding the utility of T cell engagers beyond hematologic malignancies into major solid tumors by pairing a differentiated approach to intracellular target selection with proprietary specificity engineering and novel molecule design. This strategy is designed to increase patient eligibility while maintaining the potency and selectivity required for solid tumor efficacy. Deck Bio plans to enter the clinic with its lead program, DBXO-1, in late 2027, with an initial focus on non-small cell lung cancer and other tumors in the aerodigestive tract, reaching approximately 120,000 eligible patients annually across the US, EU, and UK. Additional pipeline programs focus on expansion into additional tumor types and geographies. The founding team brings complementary expertise spanning discovery, translational development, biomarker-driven clinical execution, and company building, and is supported by an experienced group of scientific and industry advisors. Deck Bio has received awards from leading pharmaceutical companies, including Servier, Bristol Myers Squibb, Eli Lilly, and Ono Pharmaceutical, and is currently raising a $50M financing to advance DBXO-1 through a Phase 1 clinical trial and establish first-in-class clinical proof of concept.